Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma

被引:19
作者
Dodd, PM
McCaffrey, JA
Mazumdar, M
Icasiano, E
Higgins, G
Herr, H
Bajorin, DF
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Div Solid Tumor Oncol, Genitourinary Oncol Serv, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Surg, Div Urol, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
[4] Cornell Univ, Weill Med Coll, Dept Med, New York, NY USA
关键词
transitional cell carcinoma; chemotherapy;
D O I
10.1023/A:1006477823378
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: A phase II trial of pyrazoloacridine (PZA) was conducted to assess its activity and toxicity in patients with advanced transitional cell carcinoma (TCC) refractory to or progressing after one prior cisplatin-, carboplatin- or paclitaxel-based regimen. Patients and methods: PZA at a dose of 750 mg/m(2) was administered to 14 patients as a three-hour intravenous infusion on day 1 every 21 days. Premedication consisted of lorazepam 0.5-1.0 mg prior to each cycle to alleviate central nervous system toxicity. Reduction of subsequent doses was made for hematologic or central nervous system toxicity. Results: Among fourteen patients evaluable for response, no responses were observed (0% response rate; 95% confidence interval 0% to 23%). The median duration of survival for all patients was 9 months with a median follow-up of 8.5 months. Toxicity to PZA included grade 3 or 4 neutropenia in 8/14 (57%) and grade 3 or 4 thrombocytopenia in 2/14 (14%). Non-hematologic toxicity was mild. Conclusions: PZA at this dose and schedule does not have significant single-agent acitvity in patients with TCC who have failed one prior regimen.
引用
收藏
页码:247 / 251
页数:5
相关论文
共 26 条
[1]   CHEMOTHERAPY VERSUS CHEMOIMMUNOTHERAPY (CAF V CAFVP V CMF EACH +/- MER) FOR METASTATIC CARCINOMA OF THE BREAST - A CALGB STUDY [J].
AISNER, J ;
WEINBERG, V ;
PERLOFF, M ;
WEISS, R ;
PERRY, M ;
KORZUN, A ;
GINSBERG, S ;
HOLLAND, JF .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (10) :1523-1533
[2]   Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: A phase II trial [J].
Bajorin, DF ;
McCaffrey, JA ;
Hilton, S ;
Mazumdar, M ;
Kelly, WK ;
Scher, HI ;
Spicer, J ;
Herr, H ;
Higgins, G .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2722-2727
[3]  
BAJORIN DF, 1998, P AN M AM SOC CLIN, V17, pA311
[4]   ADJUVANT CHEMOTHERAPY WITH DOXORUBICIN PLUS CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL IN THE TREATMENT OF RESECTABLE BREAST-CANCER WITH MORE THAN 3 POSITIVE AXILLARY NODES [J].
BUZZONI, R ;
BONADONNA, G ;
VALAGUSSA, P ;
ZAMBETTI, M .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (12) :2134-2140
[5]  
Dreicer R, 1998, P AN M AM SOC CLIN, V17, p320a
[6]   ESTIMATING WITH CONFIDENCE [J].
GARDNER, MJ ;
ALTMAN, DG .
BRITISH MEDICAL JOURNAL, 1988, 296 (6631) :1210-1211
[7]   CISPLATIN, METHOTREXATE, AND VINBLASTINE (CMV) - AN EFFECTIVE CHEMOTHERAPY REGIMEN FOR METASTATIC TRANSITIONAL CELL-CARCINOMA OF THE URINARY-TRACT - A NORTHERN-CALIFORNIA-ONCOLOGY-GROUP STUDY [J].
HARKER, WG ;
MEYERS, FJ ;
FREIHA, FS ;
PALMER, JM ;
SHORTLIFFE, LD ;
HANNIGAN, JF ;
MCWHIRTER, KM ;
TORTI, FM .
JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (11) :1463-1470
[8]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[9]   A RANDOMIZED COMPARISON OF CISPLATIN ALONE OR IN COMBINATION WITH METHOTREXATE, VINBLASTINE, AND DOXORUBICIN IN PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA - A COOPERATIVE GROUP-STUDY [J].
LOEHRER, PJ ;
EINHORN, LH ;
ELSON, PJ ;
CRAWFORD, ED ;
KUEBLER, P ;
TANNOCK, I ;
RAGHAVAN, D ;
STUARTHARRIS, R ;
SAROSDY, MF ;
LOWE, BA ;
BLUMENSTEIN, B ;
TRUMP, D .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (07) :1066-1073
[10]   A PROSPECTIVE RANDOMIZED TRIAL COMPARING MVAC AND CISCA CHEMOTHERAPY FOR PATIENTS WITH METASTATIC UROTHELIAL TUMORS [J].
LOGOTHETIS, CJ ;
DEXEUS, FH ;
FINN, L ;
SELLA, A ;
AMATO, RJ ;
AYALA, AG ;
KILBOURN, RG .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (06) :1050-1055